dc.contributor.author | Ramaswamy, Pradeep Kakkadasam | |
dc.contributor.author | Mutsekwa, Rumbidzai | |
dc.contributor.author | Lan, Xiao | |
dc.contributor.author | Angus, Rebecca | |
dc.contributor.author | Chen, Yvonne | |
dc.contributor.author | Moattar, Hadi | |
dc.contributor.author | Edwards, John | |
dc.contributor.author | Shukla, Dheeraj | |
dc.date.accessioned | 2020-11-19T03:57:17Z | |
dc.date.available | 2020-11-19T03:57:17Z | |
dc.date.issued | 2020 | |
dc.identifier.issn | 0016-5085 | |
dc.identifier.doi | 10.1016/S0016-5085(20)33685-4 | |
dc.identifier.uri | http://hdl.handle.net/10072/399464 | |
dc.description.abstract | Background: We aimed to describe the real-world effectiveness and safety of the oral JAK inhibitor tofacitinib (tofa) in Crohn's disease (CD). Methods: We analyzed a retrospective, multi-center cohort from 3 IBD referral centers in the United States. CD pts started on tofa for active disease were included. The primary outcome was clinical response (> 50% reduction in symptoms) at week 8 determined by physician global assessment. Secondary outcomes included clinical remission at week 8. Adverse events (AEs) were recorded. Abnormal lipid.. | |
dc.language | English | |
dc.publisher | Elsevier | |
dc.relation.ispartofconferencename | Crohn's and Colitis Congress | |
dc.relation.ispartofconferencetitle | Gastroenterology | |
dc.relation.ispartofdatefrom | 2020-01-23 | |
dc.relation.ispartofdateto | 2020-01-25 | |
dc.relation.ispartoflocation | Austin, TX, USA | |
dc.relation.ispartofpagefrom | S1210 | |
dc.relation.ispartofpageto | S1211 | |
dc.relation.ispartofissue | 6 | |
dc.relation.ispartofvolume | 158 | |
dc.subject.fieldofresearch | Clinical sciences | |
dc.subject.fieldofresearch | Neurosciences | |
dc.subject.fieldofresearchcode | 3202 | |
dc.subject.fieldofresearchcode | 3209 | |
dc.subject.keywords | Science & Technology | |
dc.subject.keywords | Life Sciences & Biomedicine | |
dc.subject.keywords | Gastroenterology & Hepatology | |
dc.title | Exclusive enteral nutrition with a polymeric diet is efficacious in inducing remission in adults with active Crohn's disease | |
dc.type | Conference output | |
dc.type.description | E3 - Conferences (Extract Paper) | |
dcterms.bibliographicCitation | Ramaswamy, PK; Mutsekwa, R; Lan, X; Angus, R; Chen, Y; Moattar, H; Edwards, J; Shukla, D, Exclusive enteral nutrition with a polymeric diet is efficacious in inducing remission in adults with active Crohn's disease, Gastroenterology, 2020, 158 (6), pp. S1210-S1211 | |
dc.date.updated | 2020-11-19T03:53:05Z | |
gro.hasfulltext | No Full Text | |
gro.griffith.author | Mutsekwa, Rumbidzai | |
gro.griffith.author | Shukla, Dheeraj | |